68Ga-Fapi-46 Pet/Ct in a Metastatic Castration-Resistant Prostate Cancer Patient With Low Psma Expression

68Ga-Fapi-46 Pet/Ct in a Metastatic Castration-Resistant Prostate Cancer Patient With Low Psma Expression Publisher Pubmed

Aryana K¹ ; Manafifarid R² ; Amini H³ ; Divband G³ ; Moghadam SZ⁴

Show Affiliations

1. Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2. Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Iran
3. Khatam PET/CT Center, Khatam-al-Anbia Hospital, Tehran, Iran
4. Nuclear Medicine Center, Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran

Source: Clinical Nuclear Medicine Published:2022

Abstract

A 70-year-old man with mCRPC (metastatic castration-resistant prostate cancer) was referred for 68Ga-PSMA PET/CT for restaging and the possibility of targeted molecular radioligand therapy with 177Lu-PSMA. Numerous 68Ga-PSMA-avid skeletal metastases with low SUVs were noted. Because of low PSMA expression, a 68Ga-FAPI-46 PET/CT was performed to evaluate the eligibility for FAPI-based radioligand therapy. There were some discordant findings between 68Ga-PSMA and 68Ga-FAPI PET/CT scans regarding the detectability of lesions and SUVs. Our case signifies that 68Ga-FAPI theragnostic may have a potential role in the treatment of mCRPC patients with insignificant PSMA expression or in cases after the failure of 177Lu-PSMA therapy. © Wolters Kluwer Health, Inc. All rights reserved.

Related Docs

1. 68Ga-Fapi, a Twin Tracer for 18F-Fdg in the Era of Evolving Pet Imaging, Radiology-Nuclear Medicine Diagnostic Imaging: A Correlative Approach (2023)

2. Bone Metastasis in Prostate Cancer: Bone Scan Versus Pet Imaging, Seminars in Nuclear Medicine (2024)

Experts (# of related papers)

Reyhaneh Manafi-Farid (1)

Style	Citing Format
MLA	Aryana K, et al.. "68Ga-Fapi-46 Pet/Ct in a Metastatic Castration-Resistant Prostate Cancer Patient With Low Psma Expression." Clinical Nuclear Medicine, vol. 47, no. 11, 2022, pp. 972-973.
APA	Aryana K, Manafifarid R, Amini H, Divband G, Moghadam SZ (2022). 68Ga-Fapi-46 Pet/Ct in a Metastatic Castration-Resistant Prostate Cancer Patient With Low Psma Expression. Clinical Nuclear Medicine, 47(11), 972-973.
Chicago	Aryana K, Manafifarid R, Amini H, Divband G, Moghadam SZ. "68Ga-Fapi-46 Pet/Ct in a Metastatic Castration-Resistant Prostate Cancer Patient With Low Psma Expression." Clinical Nuclear Medicine 47, no. 11 (2022): 972-973.
Harvard	Aryana K et al. (2022) '68Ga-Fapi-46 Pet/Ct in a Metastatic Castration-Resistant Prostate Cancer Patient With Low Psma Expression', Clinical Nuclear Medicine, 47(11), pp. 972-973.
Vancouver	Aryana K, Manafifarid R, Amini H, Divband G, Moghadam SZ. 68Ga-Fapi-46 Pet/Ct in a Metastatic Castration-Resistant Prostate Cancer Patient With Low Psma Expression. Clinical Nuclear Medicine. 2022;47(11):972-973.
BibTex	@article{ author = {Aryana K and Manafifarid R and Amini H and Divband G and Moghadam SZ}, title = {68Ga-Fapi-46 Pet/Ct in a Metastatic Castration-Resistant Prostate Cancer Patient With Low Psma Expression}, journal = {Clinical Nuclear Medicine}, volume = {47}, number = {11}, pages = {972-973}, year = {2022} }
RIS	TY - JOUR AU - Aryana K AU - Manafifarid R AU - Amini H AU - Divband G AU - Moghadam SZ TI - 68Ga-Fapi-46 Pet/Ct in a Metastatic Castration-Resistant Prostate Cancer Patient With Low Psma Expression JO - Clinical Nuclear Medicine VL - 47 IS - 11 SP - 972 EP - 973 PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract